Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people begin to notice the appetite-reducing effects of Wegovy within the first one to four weeks of starting treatment, though meaningful weight loss typically builds over several months. Clinical trial data show that semaglutide 2.4mg produces its fullest results over 68 weeks, with early changes in hunger and fullness arriving well before the scales reflect them. Wegovy is a prescription-only medicine; a clinician assesses whether it is suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The landmark STEP 1 study, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Participants began at 0.25mg weekly and titrated upward roughly every four weeks, reaching the 2.4mg maintenance dose. Average body weight fell by around 15% over the full trial period. What those headline figures do not show is the shape of the curve: the sharpest rate of change typically occurs in the middle months of treatment, after the maintenance dose is established. The early weeks are dominated by something subtler. Hunger signals quieten. Portion sizes that felt normal start to feel excessive. Fullness arrives sooner and lingers longer. That internal shift, driven by semaglutide's action on GLP-1 receptors in the gut and brain, tends to precede measurable weight change by several weeks. So if you are four weeks in and the scales have barely moved, that does not mean nothing is happening. The biology is already in motion.
The NHS medicines page for semaglutide notes that it slows gastric emptying and reduces appetite — both effects that begin at the starting dose, even before you reach the therapeutic level.
The 0.25mg starting dose exists to let your digestive system adjust, not to produce rapid weight loss. Some people feel noticeably less hungry within the first week; others notice little at first. Nausea, loose stools, or mild indigestion are common in these early weeks, particularly after dose increases, and tend to settle within days. A practical point our prescribers raise often: GI side effects tend to peak in the 24 to 48 hours after an injection, not throughout the whole week. Knowing that rhythm helps people distinguish normal adjustment from something that needs attention. Most noticeable appetite suppression usually arrives by weeks two to four at the 0.25mg dose, though this is genuinely variable. For a fuller picture of how semaglutide works and what changes across the dosing schedule, the semaglutide overview on this site covers the mechanism in plain detail. What does not vary is the direction of travel: the effects build as the dose increases, which is why the four-to-five step titration schedule exists at all.
Once the maintenance dose of 2.4mg is reached, typically around week 16 to 20 for people who tolerate each step well, most people describe the most consistent appetite suppression of the whole treatment course. Food preoccupation reduces. Emotional eating patterns are easier to interrupt. Energy intake falls without the white-knuckle effort that traditional calorie restriction demands. Weight loss that felt slow in the first month often accelerates here. There is a common misconception worth gently setting aside: that Wegovy stops working after a few months. The STEP 1 data show continued weight reduction through to week 60 and beyond, though the rate of change does slow as the body approaches a new equilibrium. If you are curious how Wegovy compares to tirzepatide across that longer arc, the weight-loss treatment overview sets out the options in context. For people thinking about starting, the Wegovy page covers eligibility, the dosing pathway, and what private treatment involves. The point worth holding onto: the effects of Wegovy are not a single moment, but a progression that unfolds differently for each person.
Starting weight, metabolic rate, how consistently the injection is timed each week, and concurrent diet and activity all influence the timeline. Injection technique matters more than many people expect: consistently rotating the site (abdomen, thigh, or upper arm) and keeping the pen refrigerated per the Patient Information Leaflet prevents absorption issues that can blunt the effect. People who drink adequate water and maintain protein intake often report fewer of the GI side effects that might otherwise interrupt early treatment. If you are already on a dose elsewhere and considering moving your prescription, starting the process through a regulated online pharmacy involves a clinical review that checks your current dose and history before anything changes. A prescriber, not a form, makes that call. For general questions about when you start feeling Wegovy and what those first signs of change tend to look like, the frequently asked questions page is a practical starting point, and the Wegovy effects page goes deeper on specific changes people report. If something feels wrong at any point during treatment, the right move is to contact your prescriber directly or seek medical advice.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.